215918-21-1

Basic information

• Product Name: (S)-tert-Butyl 4,4-difluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylate
• Synonyms: (S)-tert-Butyl 4,4-difluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylate;(S)-1-Boc-2-(hydroxyMethyl)-4,4-difluoropyrrolidine;tert-butyl (2S)-4,4-difluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate
• CAS NO: 215918-21-1
• Molecular Formula: C₁₀H₁₇F₂NO₃
• Molecular Weight: 237.2436864
• Mol File: 215918-21-1.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 293.4°C at 760 mmHg
• Flash Point: 131.3°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 0.000183mmHg at 25°C
• Refractive Index: 1.465
• Storage Temp.: 2-8°C
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: (S)-tert-Butyl 4,4-difluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-Butyl 4,4-difluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylate(215918-21-1)
• EPA Substance Registry System: (S)-tert-Butyl 4,4-difluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylate(215918-21-1)

Safety Data

• Hazardous Substances Data: 215918-21-1(Hazardous Substances Data)

Usage

General Description

The chemical compound "(S)-tert-Butyl 4,4-difluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylate" is a chiral beta-amino ester with a tert-butyl group on the nitrogen atom. It also contains a difluoro substituent on the pyrrolidine ring and a hydroxymethyl group at the 2-position. (S)-tert-Butyl 4,4-difluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylate is commonly used as a building block in organic synthesis, particularly in the preparation of pharmaceuticals and agrochemicals. Its chiral nature and unique chemical structure make it a valuable intermediate in the production of complex molecules with specific stereochemical requirements.

InChI:InChI=1/C10H17F2NO3/c1-9(2,3)16-8(15)13-6-10(11,12)4-7(13)5-14/h7,14H,4-6H2,1-3H3/t7-/m0/s1

Upstream product

• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 203866-15-3 1-(tert-butoxycarbonyl)-4,4-difluoro-L-proline 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 

Downstream Products

• 1560643-31-3 C₄₁H₄₆F₄N₆O₄ 
• 1560638-96-1 C₄₅H₅₂F₄N₈O₆ 
• 1283142-42-6 (R)-2-(4,4-difluoro-1-(4-(2-methylbenzyl)phenyl)pyrrolidin-2-yl)acetic acid 
• 1283145-89-0 (R)-2-(4,4-difluoro-1-(4-(2-methylbenzyl)phenyl)pyrrolidin-2-yl)acetonitrile 
• 1283145-88-9 (R)-2-(1-(4-bromophenyl)-4,4-difluoropyrrolidin-2-yl)acetonitrile 
• 1363384-67-1 tert-butyl (2S)-2-(aminomethyl)-4,4-difluoropyrrolidine-1-carboxylate 
• 1414357-12-2 3-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4,4-difluoropyrrolidin-1-yl]-3-oxopropanenitrile 
• 1414357-07-5 tert-butyl (2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4,4-difluoropyrrolidine-1-carboxylate 
• 1337389-01-1 C₂₁H₂₅F₂NO₂Si 
• 1315585-30-8 (S)-2-(4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl)-N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)pyrrolo[2,1-f][1,2,4]triazin-2-ylthio)phenyl)acetamide 

Relevant articles and documents

CYCLIC COMPOUNDS AND METHODS OF USING SAME

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acc

MACROCYLCES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS

The present disclosure provides macrocyclic compounds comprising a 4-amido- 2,4-pentadienoate (APD) moiety. The compounds exhibit toxicity that is selective to the hypoxic micro-environments often found in cancerous tissues. The disclosed compounds are therefore suitable for treatment of hypoxic cancer cells.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.